{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:06:38Z","timestamp":1790273198856,"version":"4.1.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pediatric patients with acute leukemia are at risk of bacteremia due to disease and treatment-related toxicities. Limited data exists on pathogen distribution across different pediatric age groups. This study aims to investigate the distribution of bacterial pathogens and their susceptibility patterns across infants, children, and adolescents undergoing treatment for acute leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study that included pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) who had positive blood cultures between 01\/01\/2015\u201331\/12\/2024. Bacteremia was defined as the presence of bacterial microorganisms in the bloodstream, confirmed by one or more positive blood cultures with associated symptoms. Patients were categorized into three age groups: infants (\u22641 year), children (&gt;1 to &lt;12 years), and adolescents (\u226512 to \u226418 years). Collected data included demographics, leukemia disease risk (high, standard or low), treatment phase (induction, consolidation, maintenance, relapse, or palliative care), signs and symptoms and the causative pathogen along with its susceptibility and resistance testing. Descriptive statistics were used to summarize findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 308 bacteremia episodes among 160 patients were identified. Of these, 291 (94%) episodes occurred in ALL patients and 17 (6%) in AML patients. The median age was 5 years (IQR 3\u201311 years) with children, adolescents, and infants representing 78%, 21%, and 1%, respectively. A total of 330 bacterial isolates were identified. Isolates were most frequently recovered during consolidation (30%), induction (24%), and maintenance (23%) phases. Gram-positive organisms, particularly\n                      <jats:italic>Staphylococcus spp<\/jats:italic>\n                      . predominated across all treatment phases and age groups. Whereas a higher proportion of Gram-negative organisms \u2013 including\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella spp., and Pseudomon<\/jats:italic>\n                      as\n                      <jats:italic>spp.<\/jats:italic>\n                      \u2013 were observed among adolescents and patients in high-risk groups. Antimicrobial resistance was confined to\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      and\n                      <jats:italic>Klebsiella spp<\/jats:italic>\n                      . exhibiting Extended-Spectrum \u03b2-lactamase and Carbapenem-Resistant Enterobacterales phenotypes across the cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center descriptive study, bacteremia episodes and bacterial isolates showed descriptive differences across age groups, treatment phases, and leukemia risk categories. These findings support continued local infection surveillance. Larger multicenter studies with sufficient subgroup representation are needed to determine whether age- or phase-specific empiric therapy strategies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358779","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:23:24Z","timestamp":1790270604000},"page":"e0358779","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-6382","authenticated-orcid":true,"given":"Razan","family":"Zatarah","sequence":"first","affiliation":[{"name":"King Hussein Cancer Center","place":["Amman, Jordan"],"department":["Department of Pharmacy, Clinical Pharmacy Section"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Albdour","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center","place":["Amman, Jordan"],"department":["Department of Pharmacy, Clinical Pharmacy Section"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Assad","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center","place":["Amman, Jordan"],"department":["Department of Pharmacy, Clinical Pharmacy Section"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Budair","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center","place":["Amman, Jordan"],"department":["Department of Pediatrics, Pediatric Hematology & Oncology\/ Infectious Disease Section"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Nazer","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Center","place":["Amman, Jordan"],"department":["Department of Pharmacy, Clinical Pharmacy Section"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"5","key":"pone.0358779.ref001","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0022-3476(05)80281-1","article-title":"The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies","volume":"119","author":"PA Pizzo","year":"1991","journal-title":"J Pediatr"},{"issue":"1","key":"pone.0358779.ref002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/mdr.2019.0393","article-title":"Prevalence, epidemiology, etiology, and sensitivity of invasive bacterial infections in pediatric patients undergoing oncological treatment: a multicenter nationwide study","volume":"27","author":"O Zajac-Spychala","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"1821","key":"pone.0358779.ref003","first-page":"20143085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"AK Simon","year":"2015","journal-title":"Proc Biol Sci"},{"issue":"11","key":"pone.0358779.ref004","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/pharmaceutics17111472","article-title":"Age-Stratified clinical and microbiological profiles in pediatric infectious disease admissions: implications for risk prediction and antimicrobial stewardship","volume":"17","author":"CE Singer","year":"2025","journal-title":"Pharmaceutics"},{"key":"pone.0358779.ref005","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.ejcped.2024.100142","article-title":"Infections in children and adolescents with Acute Leukemia","volume":"3","author":"F Carlesse","year":"2024","journal-title":"EJC Paediatric Oncology"},{"issue":"4","key":"pone.0358779.ref006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4149\/neo_2011_04_326","article-title":"Blood stream infections throught the entire course of acute lymphoblastic leukemia treatment","volume":"58","author":"K Katsibardi","year":"2011","journal-title":"Neoplasma"},{"issue":"1","key":"pone.0358779.ref007","first-page":"695","article-title":"Induction therapy for acute lymphoblastic leukemia: incidence and risk factors for bloodstream infections","volume":"30","author":"RAM Silva","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"pone.0358779.ref008","article-title":"Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: a single-institution report","volume":"64","author":"AEJ Rogers","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"pone.0358779.ref009","first-page":"277","article-title":"Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment","volume":"14","author":"K Katsimpardi","year":"2006","journal-title":"Support Care Cancer"},{"issue":"3","key":"pone.0358779.ref010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/21505594.2016.1152440","article-title":"Bloodstream infections: the peak of the iceberg","volume":"7","author":"C Viscoli","year":"2016","journal-title":"Virulence"},{"key":"pone.0358779.ref011","author":"St. Jude Children\u2019s Research Hospital"},{"issue":"1","key":"pone.0358779.ref012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43046-022-00126-3","article-title":"St. Jude total therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review","volume":"34","author":"AA Omar","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9757","key":"pone.0358779.ref013","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"C Parker","year":"2010","journal-title":"Lancet"},{"issue":"35","key":"pone.0358779.ref014","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"S Jeha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0358779.ref015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"JE Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0358779.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01864-19","article-title":"The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes","volume":"58","author":"MP Weinstein","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"3","key":"pone.0358779.ref017","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","article-title":"Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria","volume":"29","author":"SH Zinner","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0358779.ref018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdw557","article-title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","volume":"28","author":"H Inaba","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0358779.ref019","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00277-013-1965-0","article-title":"Relapsing bloodstream infections during treatment of acute leukemia","volume":"93","author":"C Cattaneo","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"pone.0358779.ref020","first-page":"560","article-title":"Incidence of bloodstream infections in pediatric patients with cancer during febrile neutropenia: a retrospective study","volume":"8","author":"Y Matsukawa","year":"2025","journal-title":"JMA J"},{"issue":"6","key":"pone.0358779.ref021","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Z Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"pone.0358779.ref022","article-title":"Microbiological profiles and resistance patterns in pediatrics with cancer: an 8-year study at a comprehensive cancer center in Jordan","volume":"8","author":"D Hassouneh","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"issue":"3","key":"pone.0358779.ref023","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.ijantimicag.2022.106535","article-title":"Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019","volume":"59","author":"JA Karlowsky","year":"2022","journal-title":"Int J Antimicrob Agents"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:23:27Z","timestamp":1790270607000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358779"}},"subtitle":[],"editor":[{"given":"Nosheen","family":"Nasir","sequence":"first","affiliation":[{"name":"Aga Khan University","place":["PAKISTAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358779","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}